Results of a phase I/II trial adding carmustine (300 mg/m2) to melphalan (200 mg/m2) in multiple myeloma patients undergoing autologous stem cell transplantation.
about
Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignancies.Melphalan: old and new uses of a still master drug for multiple myeloma.Tandem chemo-mobilization followed by high-dose melphalan and carmustine with single autologous hematopoietic cell transplantation for multiple myeloma.Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial.
P2860
Results of a phase I/II trial adding carmustine (300 mg/m2) to melphalan (200 mg/m2) in multiple myeloma patients undergoing autologous stem cell transplantation.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Results of a phase I/II trial ...... ous stem cell transplantation.
@en
Results of a phase I/II trial adding carmustine
@nl
type
label
Results of a phase I/II trial ...... ous stem cell transplantation.
@en
Results of a phase I/II trial adding carmustine
@nl
prefLabel
Results of a phase I/II trial ...... ous stem cell transplantation.
@en
Results of a phase I/II trial adding carmustine
@nl
P2093
P2860
P356
P1433
P1476
Results of a phase I/II trial ...... ous stem cell transplantation.
@en
P2093
Comenzo RL
Dhodapkar M
Fleisher M
Kewalramani T
Teruya-Feldstein J
P2860
P2888
P304
P356
10.1038/SJ.LEU.2404003
P577
2006-02-01T00:00:00Z